EU Indication Restricted For Novartis's Newly Approved Piqray
Patients Previously Treated With CDK 4/6 Inhibitors Are Excluded
Piqray is now approved for use in almost 50 countries but not only did the novel drug from Novartis for advanced breast cancer take longer to be approved in the EU than in the US, its indication is narrower in the EU. This is the first of two articles based on the European public assessment report for the PIK3 inhibitor.
